MLchartDataset catalogue

dapagliflozin

Term · Oncology and biomedicine · MLC-T-ONC-012914

A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.

Table 1. Record
IdentifierMLC-T-ONC-012914
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON 
{
  "id": "MLC-T-ONC-012914",
  "term": "dapagliflozin",
  "field": "Oncology and biomedicine",
  "definition": "A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dapagliflozin/"
}

Record 5,682 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.